N
Neuropace Inc (NPCE)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
$7.97
+0.41 (+5.42%)
Market Cap: $260.45M
Last updated: Nov 17, 2026 at 11:05 AM ET
Neuropace Inc (NPCE) Valuation Multiples
Neuropace (NPCE) trades at 2.9x sales and 23.8x book value. Its P/S of 2.9x is below its 5-year median of 3.8x. Its forward P/E is 84.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 84.0x |
| Price to sales | 2.9x |
| Price to book | 23.8x |
| PEG | N/A |
| FCF yield | -4.5% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.9x | 3.8x | N/A |
| P/B | 23.8x | 15.7x | N/A |
Valuation History
Over the 5 year ends shown, its P/S ranged from 0.2x in 2021 to 5.5x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $15.44 | 5.5x | 26.5x |
| 2024 | $11.19 | 4.1x | 41.8x |
| 2023 | $10.31 | 4.0x | 12.9x |
| 2022 | $1.49 | 0.8x | 1.1x |
| 2021 | $10.08 | 0.2x | 3.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NPCE
What is NPCE's forward P/E ratio?
Neuropace has a forward P/E ratio of 84.0x.
Is NPCE stock overvalued?
GNG's valuation label for NPCE is Undervalued.
What is NPCE's price to sales ratio?
Neuropace has a price to sales ratio of 2.9x.
NPCE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts